Form 4: Xencor Director Richard Ranieri Reports RSU Grant, Option Award, and Stock Sale Under 10b5-1 Plan
Insider Transaction Report
Xencor Inc. Director Richard J. Ranieri reported the acquisition of restricted stock units and stock options, alongside a sale of common stock executed under a pre-arranged 10b5-1 trading plan.
Summary
- Director Richard J. Ranieri acquired 13,686 shares of Xencor Inc. common stock on June 12, 2025, through a grant of restricted stock units (RSUs) at a price of $0. These RSUs are set to fully vest on the first anniversary of the grant date.
- On the same date, June 12, 2025, Mr. Ranieri was granted stock options to purchase 27,372 shares of common stock at an exercise price of $9.43. These options will vest in equal monthly installments over one year, starting one month after the grant date, with full vesting by June 12, 2026.
- Mr. Ranieri sold 2,993 shares of common stock on June 16, 2025, at a price of $9.22 per share. This transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted on June 28, 2024.
- Following these transactions, Mr. Ranieri directly beneficially owns 19,183 shares of common stock and 27,372 stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The grants of RSUs and options are positive as they align director interests with shareholders, while the sale is a routine 10b5-1 transaction and not indicative of negative sentiment towards the company.
Positives
- Grant of 13,686 Restricted Stock Units (RSUs) at $0, aligning director's interests with shareholders.
- Grant of 27,372 stock options at an exercise price of $9.43, providing potential future upside.
Negatives
- Sale of 2,993 shares of common stock at $9.22, reducing direct common stock holdings.
Future Outlook
NA
Industry Context
This Form 4 filing reflects routine insider equity transactions for a director at Xencor Inc., a biotechnology company. The grants of RSUs and stock options are common forms of executive compensation in the biotech industry, designed to align management incentives with long-term shareholder value. The sale under a 10b5-1 plan indicates a pre-planned diversification or liquidity event, which is also a standard practice for insiders.
Comparison to Industry Standards
- The grant of Restricted Stock Units (RSUs) and stock options to a director is a standard practice in the biotechnology and pharmaceutical sectors, comparable to compensation structures seen at companies like Amgen, Gilead Sciences, or Regeneron Pharmaceuticals, where equity-based incentives are a significant component of executive and director compensation.
- The adoption of a Rule 10b5-1 trading plan for stock sales is a widely accepted corporate governance practice among publicly traded companies, including those in the biotech industry, to allow insiders to sell shares without concerns of insider trading, similar to plans used by executives at Pfizer or Moderna.
- The vesting schedules for both RSUs (one year) and options (monthly over one year) are typical for director equity awards, designed to encourage retention and long-term commitment, aligning with practices observed across various industries.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization of Attorney-in-Fact | Richard J. Ranieri granted Power of Attorney to Bassil I. Dahiyat, Bart Jan Cornelissen, and Celia E. Eckert to execute and file SEC Forms 3, 4, 5, and 144 on his behalf. This streamlines compliance with Section 16(a) of the Exchange Act and Rule 144. | 2025-02-19 | Enhances efficiency and ensures timely compliance with SEC reporting requirements for insider transactions, reducing administrative burden on the director. |
Stakeholder Impact
- Shareholders: The RSU and option grants align the director's long-term interests with shareholder value creation. The 10b5-1 sale is a pre-planned event and typically does not signal a change in company outlook.
- Employees: No direct impact mentioned.
- Management: The Power of Attorney streamlines compliance for the director and the company's legal/compliance team.
Next Steps
- The 13,686 Restricted Stock Units are expected to fully vest on the first anniversary of the grant date (June 12, 2026).
- The 27,372 stock options will vest in equal monthly installments over one year, beginning on the one-month anniversary of June 12, 2025, with full vesting by June 12, 2026.
Key Dates
| Date | Description |
|---|---|
| 2024-06-28 | Date Reporting Person adopted the 10b5-1 trading plan. |
| 2025-02-19 | Date Power of Attorney was executed by Richard J. Ranieri. |
| 2025-06-12 | Date of acquisition of 13,686 Restricted Stock Units and 27,372 Stock Options. |
| 2025-06-16 | Date of sale of 2,993 shares of common stock and filing date of the Form 4. |
| 2026-06-12 | Date by which all 27,372 stock options will be fully vested. |
| 2035-06-11 | Expiration date of the 27,372 stock options. |
Recommendation
holdKeywords
Xencor Inc., XNCR, Form 4, Insider Trading, Richard J. Ranieri, Restricted Stock Units, RSU, Stock Options, 10b5-1 Plan, Director Stock Transactions, Equity Compensation, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.